Microphysiological Systems (MPS) for Studying T2D, Obesity, and Their Complications

Event Details

Purpose

Microphysiological systems (MPS) are in vitro systems that aim to recapitulate higher orders of cell/tissue organization than conventional two-dimensional static cultures and enable disease modeling and drug discovery studies. Advances in biomaterials, microfluidics, and tissue engineering allow for greater control of three-dimensional cell cultures containing multiple cell types and constituting more physiological tissue organization. The connection of chambers allows inter-organ crosstalk. The use of patient samples and human induced pluripotent stem cell–derived cells may someday enable patient-on-a-chip or clinical-trial-on-a-chip studies for many disease processes that are high priority for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Challenges in this field of research include the need for multidisciplinary team science, evolving protocols for stem cell differentiation to obtain mature cell types, and balancing the system complexity with reproducibility and throughput.

Meeting Objectives

• Gauge the current status of using MPS for research on type 2 diabetes (T2D), obesity, and their complications.
• Determine the knowledge gaps that are difficult to study directly in humans and for which traditional in vitro systems and animal models are inadequate.
• Identify opportunities to use MPS to increase our understanding of T2D, obesity, and kidney diseases.
• Determine realistic goals that could be accomplished in the next 1, 5, and 10 years.

Organizing Committee

• Linda Griffith, Ph.D., Professor of Teaching Innovation, Massachusetts Institute of Technology
• David D’Alessio, M.D., James B. Wyngaarden Distinguished Professor of Medicine, Chief, Division of Endocrinology and Metabolism, Duke University
• Joseph Bonventre, M.D., Ph.D. Chief, Division of Renal Medicine, Chief, Division of Engineering in Medicine, and Professor, Brigham and Women’s Hospital, Harvard Medical School
• Eric Brunskill, Ph.D., Program Director, Division of Kidney, Urologic, & Hematologic Diseases, NIDDK, National Institutes of Health (NIH)
• Bonnie Burgess-Beusse, Ph.D., Program Director, Division of Digestive Diseases & Nutrition, NIDDK, NIH
• Daniel Gossett, Ph.D., Program Director, Division of Kidney, Urologic, & Hematologic Diseases, NIDDK, NIH
• Carol Renfrew Haft, Ph.D., Program Director, Division of Diabetes, Endocrinology, & Metabolic Diseases, NIDDK, NIH
• Albert Hwa, Ph.D., Program Director, Division of Diabetes, Endocrinology, & Metabolic Diseases, NIDDK, NIH

Registration Deadline

September 21, 2023

Agenda

September 28, 2023

8:00 a.m. – 8:20 a.m

Welcome Remarks and Introductions
Griffin P. Rodgers, M.D., M.A.C.P., Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
William Cefalu, M.D., Director of Endocrinology, Diabetes, and Metabolic Diseases, NIDDK, NIH

8:20 a.m. – 9:35 a.m.

Session I: Setting the Stage—Establishing the Current State of the Art
Moderator: Murat Cirit, Ph.D., Javelin Biotech

Andreas Stahl, Ph.D., University of California, Berkeley
Linda Griffith, Ph.D., Massachusetts Institute of Technology
Edward Kelly, Ph.D., University of Washington

9:35 a.m. – 9:50 a.m.

Session Panel Discussion

9:50 a.m. – 10:00 a.m.

Break

10:00 a.m. – 11:15 a.m.

Session II: Organoids on Chips, Tissue Niche, and Proper Cell/Structural Compositions
Moderator: Alison Kohan, Ph.D., University of Pittsburgh

Catherine Yeung, Pharm.D., Ph.D., University of Washington
James Wells, Ph.D., Cincinnati Children’s Hospital Medical Center
Christopher Hughes, Ph.D., University of California, Irvine

11:15 a.m. – 11:30 a.m.

Session Panel Discussion

11:30 a.m. – 12:30 p.m.

Lunch

12:30 p.m. – 1:45 p.m.

Session III: Microphysiological Systems (MPS) Modeling of Intra-organ Crosstalk
Moderator: Ashutosh Agarwal, Ph.D., University of Miami

Bryan Bergman, Ph.D., University of Colorado
Ed Phelps, Ph.D., University of Florida
Zhongwei Li, Ph.D., University of Southern California

1:45 p.m. – 2:00 p.m.

Session Panel Discussion

2:00 p.m. – 3:40 p.m.

Session IV: Multi-Organ Cross-Talk: Bridging Clinical Findings with MPS
Moderator: Mark Herman, M.D., Baylor College of Medicine

Clair Crewe, Ph.D., Washington University
Rebecca Haeusler, Ph.D., Columbia University
Martin Trapicar, Ph.D., Johns Hopkins University
Peter Loskill, Ph.D., University Tübingen

3:40 p.m. – 3:55 p.m.

Session Panel Discussion

3:55 p.m. – 4:05 p.m.

Break

4:05 p.m. – 5:45 p.m.

Session V: MPS as a Tool to Understand Disease Heterogeneity and Precision Medicine
Moderator: Benjamin Freedman, Ph.D., University of Washington

Takanori Takebe, Ph.D., Cincinnati Children’s Hospital Medical Center
Josef Penninger, M.D., Helmholtz Centre for Infection Research
Roos Masereeuw, Ph.D., Utrecht University
Scott Noggle, Ph.D., New York Stem Cell Foundation

5:45 p.m. – 6:00 p.m.

Session Panel Discussion

6:00 p.m.

Adjournment

September 29, 2023

8:00 p.m. – 9:15 a.m.

Session VI: Mathematical Modeling in Conjunction with MPS
Moderator: Martin Trapecar, Ph.D., Johns Hopkins University

Barbara Nikolajczyk, Ph.D., University of Kentucky
Murat Cirit, Ph.D., Javelin Biotech
Mark Schurdak, Ph.D., University of Pittsburgh

9:15 a.m. – 9:30 p.m.

Session Panel Discussion

9:30 a.m. – 10:45 a.m.

Session VII: Translational Gaps and Utility for Drug Screening
Moderator: Simi Ahmed, Ph.D., New York Stem Cell Foundation

Jacob Jeppesen, Ph.D., Novo Nordisk
Kristin Bircsak, Ph.D., Mimetas
D. Lansing Taylor, Ph.D., University of Pittsburgh

10:45 a.m. – 11:00 a.m.

Session Panel Discussion

11:00 a.m. – 12:00 p.m.

Session VIII: Moderator-directed Panel Discussion

12:00 p.m. – 12:15 p.m.

Meeting Wrap-up and Summary

12:15 p.m.

Meeting Adjournment